Dividendos de Novonesis

Dividendo controles de criterios 0/6

Novozymes es una empresa que paga dividendos con una rentabilidad actual de 0.85%.

Información clave

0.8%

Rentabilidad por dividendo

108%

Ratio de pago

Rentabilidad media de la industria	2.5%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	DKK 4.000
Beneficios por acción	DKK 0.61
Previsión de rentabilidad por dividendo	1.5%

Últimas actualizaciones de dividendos

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: NSIS B no paga un dividendo notable para el mercado Danish, por lo que no es necesario comprobar si los pagos son estables.

Dividendo creciente: NSIS B no paga un dividendo notable para el mercado Danish, por lo que no es necesario comprobar si los pagos aumentan.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Novonesis vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de NSIS B con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (NSIS B)	0.8%
Suelo de mercado 25% (DK)	1.5%
Techo de mercado 25% (DK)	5.5%
Media de la industria (Chemicals)	2.5%
Analista de previsiones (NSIS B) (hasta 3 años)	1.5%

Dividendo destacado: El dividendo de NSIS B(1.46%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Danish (1.67%).

Alto dividendo: El (1.4%) del dividendo de NSIS B es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Danish (5.77%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: NSIS B no paga un dividendo notable para el mercado Danish.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: NSIS B no paga un dividendo notable para el mercado Danish.

Dividendos de Novonesis

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Upcoming dividend of kr.6.00 per share at 1.8% yield

Recent updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly